A cura di Ivana Pariggiano
Elevati livelli di colesterolo aumentano il rischio di aterosclerosi e malattie cardiovascolari. L’American Heart Association (AHA) e l’American College of Cardiology (ACC) hanno proposto nuove linee guida basate sulle evidenze scientifiche emerse negli ultimi …
A cura di Carmelo La Greca
Caroline Sindet-Pedersen, Morten Lamberts, Laila Staerk, Anders Nissen Bonde, Jeffrey S Berger, Jannik Langtved Pallisgaard, Morten Lock Hansen, Christian Torp-Pedersen, Gunnar H Gislason, Jonas Bjerring Olesen. Combining Oral Anticoagulants With Platelet Inhibitors in …
A cura di Ivana Pariggiano
G.G. Schwartz et Al. November 7, 2018, at NEJM.org. DOI: 10.1056/NEJMoa1801174
I pazienti affetti da sindrome coronarica acuta rappresentano una popolazione ad alto rischio di recidiva di eventi cardiovascolari, soprattutto coloro che mantengono …
A cura di Ilaria Cavallari
Matsumura-Nakano et al. An Open-Label Randomized Trial Comparing Oral Anticoagulation with and without Single Antiplatelet Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease Beyond One Year after Coronary Stent Implantation: The …
A cura di Ilaria Cavallari
Van der Wall et al. Idarucizumab for Dabigatran Reversal in the Management of Patients with Gastrointestinal Bleeding. Circulation 2018 Online.
Sebbene il dabigatran abbia un profilo rischio-beneficio favorevole rispetto alla terapia con antagonisti …
A cura di Ilaria Cavallari
Patti G, et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy – A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J …
A cura di Marta F. Brancati
Kofoed KF, Kelbaek H, Riis Hansen P, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: The VERDICT (Very EaRly vs Deferred Invasive evaluation …
A cura di Marta F. Brancati
Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet …
A cura di Ilaria Cavallari
Zannad F, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018 Aug 27. doi: 10.1056/NEJMoa1808848. [Epub ahead of print]
L’insufficienza cardiaca è associata …